Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|RB1 I101fs RB1 E268* RB1 V654fs RB1 T738_R775del||Her2-receptor negative breast cancer||predicted - resistant||Fulvestrant + Palbociclib||Case Reports/Case Series||Actionable||In a clinical case study, RB1 mutations including E268*, I101fs, T738_R775del, and V654fs were identified in the circulating tumor DNA of a patient with estrogen receptor positive, progesterone receptor positive, and Erbb2 (Her2)-negative, invasive ductal carcinoma at the time of disease progression after 8 months of Ibrance (palbociclib) and Faslodex (fulvestrant) combination treatment (PMID: 29236940).||29236940|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|